

ADVANCING DIVERSITY IN CLINICAL TRIALS

Representation matters in every part of society, but especially when lives are on the line. Clinical trials must enrol participants who are representative of the wider world and disease population, but this is not being extensively achieved. This infographic explores diversity in US clinical trials and the pharmaceutical industry's efforts to address the deficits

PHARMA'S EFFORTS TO IMPROVE CLINICAL TRIAL DIVERSITY

Top company initiatives

Amgen ■
Launched Representation in Clinical Research (RISE) to address systemic issues that deter people from participating in trials, especially those who have been historically excluded

BMS Foundation ■
Committed \$100m to train and develop 250 new clinical investigators who are either racially and ethnically diverse or committed to increasing diversity in trials

Pfizer ■
Announced a 3-year, \$10m grant to establish Columbia-Pfizer Clinical Trials Diversity Initiative, targeting underrepresentation of minority groups as clinical trial researchers

GSK ■
Set a target to ensure over 70% of interventional clinical trials have a clear demographic plan aligned with the target disease's epidemiology

Johnson & Johnson ■
Launched the Race to Health Equity initiative with a \$100m commitment to promote health equity solutions by 2027

Eli Lilly ■
Provided \$500,000 of seed money towards a network in Indiana focused on community public health research and aimed at improving diversity in clinical trials

Collaborative industry schemes

2020 ■ **PhRMA principles**
Industry-wide commitment to enhancing clinical trial participation by improving diversity among clinical investigators, identifying and tackling access barriers, bolstering individual health literacy and increasing the use of real-world data post-approval


2021 ■ **Beacon of Hope**
Novartis, Sanofi and Merck partnership with over 26 historically black universities and medical schools. A 10+ year collaboration to create programmes that address the root causes of disparities in health and education, creating greater diversity, equity and inclusion

2022 ■ **Digital Medicine Society**
Acclinate, Amgen, GSK, Lightship, Medable, Rubix L.S, Sage Bionetworks, Savvy Cooperative and THREAD collaboration to drive inclusion in digital clinical trials by providing tools and frameworks to integrate diverse perspectives in planning process for trials of this kind.

Source: Alva, 2022

TRIAL DEMOGRAPHICS UNDER THE MICROSCOPE

Representation in US cancer trials over the last 15 years



A closer look

Despite being the **2nd** and **3rd** most represented groups in clinical trials


48% of trials did not include Hispanic American patients and

42% of trials did not include Black and African American patients

Source: Phesi, 2022

A CASE FOR GREATER AWARENESS

Patients who have never heard of a clinical trial



Source: Deloitte, 2022

A FRAMEWORK FOR IMPROVEMENT

Changing the paradigm to increase clinical trial diversity

Disparate sites at varying levels of readiness and community connectiveness



Create an infrastructure that provides:

- A network
- Communications
- Community relationships
- Ongoing on-site training
- Sustainable support
- Standardised platforms and metrics



A sustainable, community-based infrastructure supporting multiple touchpoints and sites dedicated to clinical trial diversity

Source: PhRMA, 2022